An assessment of nucleic acid amplification testing for active mycobacterial infection



Yüklə 3,88 Mb.
səhifə72/143
tarix04.01.2022
ölçüsü3,88 Mb.
#60347
1   ...   68   69   70   71   72   73   74   75   ...   143
Population

Patients with clinical signs and symptoms of active TB whose specimen is suitable for AFB microscopy and culture, and who have had < 3 days of anti-TB treatment

Subpopulations for analysis:



  1. those with a high pre-test probability of active TB, e.g. come from a country with high rates of TB, versus those with a low pre-test probability of TB

Intervention

  1. AFB microscopy plus NAAT for the detection of MTB-complex DNA ± culture

  2. NAAT for the detection of genetic mutations on the rpoB gene associated with rifampicin resistance

Comparators

  1. AFB microscopy ± culture

  2. No NAAT for rifampicin resistance, ongoing AFB tests to determine if patient is responding to treatment

Outcomes

Time to diagnosis of TB or alternate condition, time to diagnosis of resistance, time to appropriate treatment, rate of treatment, duration of treatment, number of contacts required to be traced, number of contacts infected, rate of rifampicin resistance

Study design

Randomised trials, cohort studies, case series or systematic reviews of these study designs

Search period

1990 – May 2014 or inception of the database if later than 1990

Language

Studies in languages other than English were excluded unless they represented a higher level of evidence than that available in the English language evidence-base

Seventeen studies reporting change in management outcomes due to NAAT were identified. Eight of these studies were conducted in developing countries with a high TB-prevalence (e.g. South-Africa, Uganda, Peru) and 8 studies were conducted in low-prevalence countries (e.g. USA, UK, Canada). The remaining study was conducted in a country with an intermediate TB burden (Korea). Only two studies used in-house NAATs and the remainder used commercial NAAT, of which 12 used the Xpert NAAT. The study profiles are summarised in Table (Appendix ) and an overall summary of the body of evidence is presented in Table .

Table Body of evidence matrix for studies reporting change in management outcomes due to NAAT




Yüklə 3,88 Mb.

Dostları ilə paylaş:
1   ...   68   69   70   71   72   73   74   75   ...   143




Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©muhaz.org 2024
rəhbərliyinə müraciət

gir | qeydiyyatdan keç
    Ana səhifə


yükləyin